Highlights and commentary on key AACR21 data presentations
It’s time for some commentary and insights regarding important emerging data from the AACR meeting.
The route to success in oncology R&D is always paved with gold, after all, although big ticket acquisitions may take some of the sting out of the tail.
As always, there were some hidden gems in the AACR21 program — in the first of our post meeting critiques, we take a careful look at the what’s behind the veneer.
We have a round baker’s dozen of early new product development compounds and explore them all to find out what interesting, as well as where there are potential pointers for future challenges which may need to be addressed…
To learn more about the AACR21 data and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
